- Home
- SLNO
as 11-07-2025 3:53pm EST
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 3.7B | IPO Year: | 2014 |
| Target Price: | $114.89 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $41.50 - $90.32 | Next Earning Date: | 11-04-2025 |
| Revenue: | $98,675,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 181.30% |
Latest Soleno Therapeutics Inc. News
SLNO Breaking Stock News: Dive into SLNO Ticker-Specific Updates for Smart Investing
Insider Monkey
3 days ago
Soleno Therapeutics (SLNO) Ends 26% Lower After Q3 Earnings
Simply Wall St.
3 days ago
Soleno Therapeutics (SLNO): Losses Accelerate 43.6% Annually, Challenging Bullish Profitability Narrative
MT Newswires
4 days ago
Top Premarket Decliners
BioPharma Dive
4 days ago
Soleno slumps despite sales uptick; Madrigal’s MASH drug continues ascent
MT Newswires
4 days ago
Soleno Therapeutics Swings to Q3 Profit; Shares Fall After-Hours
GuruFocus.com
4 days ago
Soleno Therapeutics Inc (SLNO) Q3 2025 Earnings Call Highlights: Profitability Achieved Amidst ...
GlobeNewswire
5 days ago
Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR
GuruFocus.com
6 days ago
Soleno Therapeutics Inc (SLNO) Q3 2025 Earnings Report Preview: What To Look For
Compare SLNO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLNO Soleno Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.